Review articles cover how pre-MEASURE has impacted clinical decision-making and the interpretation of NPM1 MRD throughout the treatment course of AML. Other manuscripts address the limitations of ...
The company recently announced that its pivotal Phase 2 KOMET-001 trial in relapsed/refractory NPM1-mutated AML met ... and minimal residual disease (MRD) negativity in challenging AML frontline ...
KOMET-001 registrational trial in R/R NPM1-mutant AML achieved primary endpoint – – Alignment reached with FDA and EMA on key aspects of the KOMET-017 protocol including use of MRD-negative CR ...
Good day, everyone, and welcome to today's Q4 2024 Kura Oncology, Inc., financial results conference call. (Operator Instructions) Please note this call is being recorded. It is now my pleasure to ...
13d
Kura Oncology Inc (KURA) reports significant revenue growth and strategic progress in its Q4 2024 earnings call, setting the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback